List of Vaccines Companies in Canada - 26

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

BioVaxys Technology Corp. (CSE:BIOV, OTCQB:BVAXF, FR:5LB), formerly BioVaxys LLC, is a British Columbia-registered clinical-stage biotechnology company dedicated to improving patient lives with novel immunotherapies based on our DPX™ immune-educating delivery technology platform and our HapTenix© neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase IIb clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using our proprietary HapTenix© neoantigen tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. BioVaxys is capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens.

Expertise in both microbial fermentation and chemical synthesis allows us to tackle today's development pipeline's increasingly complex molecules. In fact, we thrive on the vexing challenges few CDMOs would have either the expertise or desire to address. Bold vision, along with the passion and commitment to make that vision reality, is at the heart of our organization. We are a forward-thinking, North American CDMO Pharmaceutical company specializing in clinical-to-commercial scale production capabilities for: Synthetic small molecules Fermented small molecules Highly potent APIs Biologics Bioreagents Flexibility, creativity, and dedication to process optimization are at the heart of our method and process development as well as quality and compliance efforts. We assure the programs advance on time and with the highest quality outcomes under our project managers' leadership.

Defence Therapeutics is a publicly-traded (CSE: DTC, OTCQB: DTCFF, FSE: DTC) clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company. A new reality in genetic medicine lies ahead, one that will be ushered in with the advent of safe, effective, and redosable nucleic acid delivery technologies. At Entos, we develop next generation genetic medicines using our proprietary Fusogenix proteolipid vehicle (PLV) drug delivery system. Fusogenix PLVs are formulated with FAST proteins to enable the delivery of nucleic acid into target cells through direct fusion.

A newly established NewCo developing therapeutics targeting a novel class of tumour-specific antigen.

Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications.

At Eyam, our mission is to bring “Next Generation” vaccine and therapeutic technologies to market to solve today's health care needs.

IntelliStem, Inc. is a clinical-stage biotech that develops innovative cellular immune cancer therapy approaches. The Company has demonstrated the...

KisoJi is dedicated to developing multi-specific antibody technologies and therapeutics that improve outcomes in oncology.

Microbix Biosystems Inc. develops and commercializes proprietary biological and technological solutions for human health and wellbeing. We manufacture a wide range of biological materials for the global diagnostics industry, notably antigens used in immunoassays and Quality Assessment Products (QAPs™). In 2021 we launched our first Viral Transport Medium, branded as DxTM. Microbix’s business of producing high-quality viral and bacterial preparations stems from over three decades of experience in the field, including strain selection, reliable and efficient organism culture at scale, purification, and pathogen inactivation. As a result of Microbix’s expertise, its products have received widespread and longstanding customer acceptance, with continuing growth in demand. Microbix’s current catalogue of biological preparations covers a range of pathogens that are implicated in maternal, pediatric, childhood, respiratory, sexually transmitted, and insect-borne diseases. Microbix also applies its biological expertise to develop other innovative and proprietary technologies and products. Our development project pipeline currently includes Kinlytic® Urokinase, a biologic thrombolytic drug used to treat blood clots.

Nicoya is a Canadian biotechnology company dedicated to improving human life by helping scientists succeed. Established in 2012, Nicoya was founded by Ryan Denomme in his relentless pursuit to use nanotechnology to increase the affordability and ease of use of scientific instruments. Within 10 years, Nicoya has grown to a team of 100+ employees who have extensive experience working at the forefront of nanotechnology and biotechnology sectors. Nicoya develops innovative and accessible biosensor technology for in-depth characterization of biomolecular interactions. Alto, the world's first digital high-throughput benchtop SPR instrument, is capable of accelerating drug discovery using a fraction of sample volume traditionally required for biomolecular interaction analyses. Alto helps biotechnology and pharmaceutical companies go-to-market faster with increased efficiency and success early in their product pipelines. Join us on our mission to improve human life by helping scientists to succeed. For job opportunities, see our webpage at https://nicoyalife.com/about/careers/

Orbital Farm isa global agri tech company supplying fresh vegetables, fish, and vegan protein to local markets around the world. The company uses advanced technologies such as clean tech, robotics and automation.

pHLIP, Inc. was founded to bring its proprietary pHLIP® Platform Technology to the clinic, aiming to improve the treatment of diseases where visualization and targeted therapy would be highly advantageous. The possible applications of the technology are wide-ranging, including cancer, inflammation and fibrosis. Our dreams for the improvement of medicine include many possibilities: Imaging of the blood will allow the local circulation to be continuously monitored during surgery. Marking the surfaces of tumor cells will guide efficient and conservative removal of tumors or will activate the immune system to attack the tumor. Targeting of effective agents will alleviate inflammation. Targeted delivery of agents to cells in tumors will broaden the range of therapeutics while suppressing side effects.

PnuVax Incorporated is dedicated to the production of high quality biopharmaceuticals for the promotion of public health worldwide.

Precision NanoSystems, now part of Cytiva, is a global leader in ushering in the next wave of genomic medicines in infectious diseases, cancer, and rare diseases. We work with the world's leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genomic medicines.

ProMIS Neurosciences, Inc. is a leading development-stage biotechnology company based in Toronto, Ontario and Cambridge, Massachusetts. The company is focused on the treatment of Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy through the development of antibody therapeutics and diagnostics. ProMIS Neurosciences is publicly traded on the Toronto Stock Exchange.

ProMIS Neurosciences is focused on the treatment of Alzheimer’s disease, amyotrophic lateral sclerosis and multiple system atrophy through the discovery and development of antibodies selective for toxic misfolded proteins driving these diseases.

Providence Therapeutics Holdings Inc is a clinical-stage biotechnology company focused on drug development and platform development. The Providence mRNA Medicines platform is comprised of four integrated platforms: 1) mRNA Medicines Platform, 2) NextGen lipid nanoparticles (LNP), 3) Manufacturing Platform and 4) Regulatory Platform. Providence’s mRNA and NextGen LNP platform offer an end-to-end solution for designing codon-optimized ultrapure mRNA that can be formulated in application optimized LNP. The Providence proprietary NextGen LNP, consists of rationally designed lipids that have been tested for suitability for programs in oncology, infectious diseases and gene delivery. Our scalable, efficient platform demonstrates differentiated capabilities in mRNA design, manufacturing, and formulation processes, as well as specific organ and tissue targeting. For more information, please visit providencetherapeutics.com

Le Centre de recherche du CHUQ est une composante du Centre hospitalier universitaire de Québec (CHUQ) qui dessert la région métropolitaine de Québec et l’Est du Québec. Le CHUQ est affilié à l’Université Laval. Le CRCHUQ est issu de la fusion des centres de recherche des hôpitaux formant le Centre hospitalier universitaire de Québec (CHUQ), soit le CHUL, L’Hôtel-Dieu de Québec et l’Hôpital Saint-François d’Assise. Les équipes de recherche regroupées sous huit axes opèrent sur les trois sites hospitaliers. Le CRCHUQ, grâce à l’excellence de ses équipes de recherche et de ses installations ultramodernes, possède une réputation enviable au niveau national et international. Reconnu par le FRSQ, le CRCHUQ a conclu avec l’Université Laval un partenariat qui lui permet de maintenir et de développer un regroupement d'expertise et d'excellence de même qu’un milieu de formation de chercheurs et de professionnels de la santé dans chacun des domaines de recherche retenus. Le Centre collabore avec d'autres milieux de recherche et assure à la communauté scientifique des services spécialisés qui ne sont pas disponibles ailleurs. Le CRCHUQ se situe parmi les plus importants centres de recherche en milieu hospitalier au Canada. Les 259 chercheurs et leurs équipes concentrent leurs travaux dans les domaines de recherche suivants : * Cancer * Endocrinologie et génomique * Infectiologie et immunologie * Métabolisme, santé vasculaire et rénale * Neurosciences * Reproduction, santé périnatale et santé de l’enfant * Santé des populations et environnementale * Transfert des connaissances et évaluation des technologies et des modes d’intervention en santé

The University of Alberta is one of Canada's top teaching and research universities, with an international reputation for excellence across the humanities, sciences, creative arts, business, engineering, and health sciences. Home to more than 39,000 students and 15,000 faculty and staff, the university has an annual budget of $1.7 billion and attracts nearly $450 million in sponsored research revenue. The U of A offers close to 400 rigorous undergraduate, graduate, and professional programs in 18 faculties on five campuses. The university has more than 250,000 alumni worldwide. The university and its people remain dedicated to the promise made in 1908 by founding president Henry Marshall Tory that knowledge shall be used for "uplifting the whole people."​

Ivey Business School (Ivey) focuses on developing leaders with case-based and experiential learning at the core of its curriculum. In addition, Ivey contributes to knowledge creation and application through the scholarly and practice-oriented work of faculty and through the support and outreach of its Research Centres and Institutes. Ivey offers degree programs at the undergraduate level (Honours Business Administration) and post graduate levels (Full-time MBA, Accelerated MBA, Executive MBA, MSc in Management, Master of Management in Analytics, and PhD) as well as non-degree executive development, open enrollment, and customized corporate programs through The Ivey Academy. Ivey is affiliated with Western University with its main campus located in London, Ontario, midway between Toronto and Detroit. The School also has three executive teaching facilities: Ivey’s Donald K. Johnson Centre located in the Exchange Tower in Toronto’s financial district, at the Spencer Leadership Centre in London, Ontario, and the Cheng Yu Tun Management Institute in the Hong Kong Convention and Exhibition Centre.

To strengthen Canada’s role in responding to infectious diseases, the University of Saskatchewan's Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) works with international partners to study human and animal pathogens and develop solutions.With 150 interdisciplinary personnel, over $200 million in containment infrastructure, and more

Virogin Biotech is a biotechnology company that specializes in oncolytic virus drug development to create impactful drugs for patients with the highest medical need.